3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
6
Sarcoma, Alveolar Soft Part
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Rectal Neoplasms
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Lymphoma
1
Endometrial Neoplasms
1
Diarrhea
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Chondrosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma in Situ
1
Interventions
Carboplatin
41
Paclitaxel
40
pembrolizumab
38
Cyclophosphamide
23
Gemcitabine
22
130-nm albumin-bound paclitaxel
21
Doxorubicin
18
Cisplatin
18
Albumin-Bound Paclitaxel
18
atezolizumab
16
Taxes
15
Capecitabine
13
veliparib
10
Nivolumab
9
Docetaxel
9
Bevacizumab
9
olaparib
8
liposomal doxorubicin
7
Everolimus
7
spartalizumab
6
durvalumab
6
Epirubicin
6
trametinib
5
pegfilgrastim
5
eribulin
5
Irinotecan
5
Filgrastim
5
iniparib
4
binimetinib
4
apatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Triple Negative Breast Neoplasms
×
Loperamide
×
Clear all
NCT05520723
2025-12-04
PRIMED
MedSIR
Phase 2
Completed
50 enrolled